Hims & Hers Health Q1 2026: Revenue Misses, Net Loss Widens as GLP-1 Pivot Reshapes the Business

Hims & Hers posted $608.1M in Q1 2026 revenue — up 4% year-over-year but below the $616.8M Wall Street consensus — while swinging to a net loss of $0.40 per share amid a sweeping strategic overhaul of its weight-loss segment.

A Quarter Defined by Transition Costs and Strategic Repositioning

Hims & Hers Health, Inc. (NYSE: HIMS) reported first-quarter 2026 financial results on May 11, 2026, revealing a company in deliberate — and costly — transition. Total revenue came in at $608.1 million, up from $586.0 million in the first quarter of 2025, a 4% year-over-year gain. The figure fell short of the $616.8 million consensus estimate, contributing to a sell-off of more than 11% in after-hours trading on the day of the announcement.

The headline miss, however, reflects a calculated pivot rather than a deterioration of the underlying platform. The company executed a major strategic shift in its U.S. weight loss offering, transitioning away from compounded GLP-1 medications toward branded products — a move that compressed margins, triggered one-time restructuring charges, and temporarily weighed on domestic revenue.

Domestic Decline Offset by International Explosion

The geographic breakdown of Q1 2026 revenue tells a tale of two businesses. U.S. revenue declined 8% year-over-year to $529.9 million, from $578.7 million in the prior-year period, as the GLP-1 product transition reduced volume in the company's largest segment. Meanwhile, Rest of World revenue surged 969% to $78.2 million, compared to just $7.3 million in Q1 2025, reflecting the rapid scaling of Hims & Hers' international operations.

Subscriber growth remained a bright spot. The platform ended the quarter with nearly 2.6 million subscribers, up 9% from 2.366 million a year earlier. Monthly revenue per average subscriber, however, declined 6% to $80, down from $85 in Q1 2025, reflecting the mix shift toward lower-priced branded GLP-1 offerings and structural changes in the product portfolio.

Margin Compression and the Weight of Restructuring

Gross margin contracted sharply, dropping to 65% in Q1 2026 from 73% in Q1 2025, as cost of revenue jumped to $211.3 million from $155.3 million a year earlier. The widening cost structure was largely driven by $28.5 million in non-cash restructuring charges embedded within cost of revenue, stemming directly from the company's 2026 U.S. weight-loss announcement — including inventory write-downs associated with exiting the compounded semaglutide business.

Excluding these one-time items, adjusted gross margin stood at 70%, a more modest but still meaningful compression from 73% a year ago.

Total operating expenses climbed to $475.1 million from $372.8 million in Q1 2025. General and administrative expenses more than doubled year-over-year to $109.7 million, incorporating $15 million in legal settlement costs and $13.4 million in acquisition and transaction-related costs tied to the company's international expansion activity. Technology and development spending also surged 57% to $46.9 million, signaling aggressive investment in AI-driven personalization infrastructure.

The company reported an operating loss of $78.3 million, a sharp reversal from operating income of $57.9 million in Q1 2025. Net loss totaled $92.1 million, or -$0.40 per diluted share, against a year-ago net income of $49.5 million, or $0.20 per diluted share.

Adjusted EBITDA and Free Cash Flow Hold Ground

On a non-GAAP basis, Adjusted EBITDA came in at $44.3 million, compared to $91.1 million in Q1 2025, representing a 7% Adjusted EBITDA margin versus 16% in the prior-year quarter. The contraction reflects both the strategic transition costs and the accelerated build-out of the company's closed-loop healthcare ecosystem.

Despite the swing to a net loss, free cash flow remained positive at $53.0 million, up from $50.1 million a year ago, supported by $89.4 million in net cash from operating activities. The company ended the quarter with $222.3 million in cash and cash equivalents and $528.6 million in short-term available-for-sale investments, providing a combined liquidity position of approximately $750 million to fund ongoing operations and strategic deployment.

Eucalyptus Acquisition and the Global Ambition

A significant driver of Q1's elevated costs was the acquisition of Eucalyptus, an Australian digital health platform. The company deployed $137.9 million in cash for business acquisitions during the quarter, with goodwill rising to $342.8 million and intangible assets climbing to $261.0 million from $196.1 million at year-end 2025. The Eucalyptus deal is expected to close in mid-2026, subject to regulatory approvals, and is excluded from current forward guidance.

The acquisition forms a cornerstone of the company's ambition to become the world's largest consumer health platform by 2030, a target tied to long-term goals of at least $6.5 billion in annual revenue and $1.3 billion in Adjusted EBITDA.

Branded GLP-1 Pivot and the Novo Nordisk Factor

The quarter's most consequential development was the formal pivot to branded GLP-1 medications in the U.S. weight loss segment. Hims & Hers transitioned its U.S. offering to mirror its global approach — providing access to branded GLP-1 drugs while limiting compounded alternatives to a narrow scope. This shift followed regulatory pressure on compounded semaglutide and reflected the company's partnership framework with major pharmaceutical players including Novo Nordisk.

Early demand signals from the new branded offering showed meaningful broadening of consumer reach, with management noting encouraging uptake among new subscriber cohorts. The company's ability to convert those early signals into sustained revenue growth will be the defining test of the strategy heading into the second half of 2026.

Raised Guidance Signals Confidence in Acceleration

Despite the headline miss, Hims & Hers management moved to reassure markets by raising its full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion, above the prior consensus of approximately $2.72 billion. This implies 19% to 28% year-over-year growth and signals conviction that the GLP-1 transition will drive material acceleration in the coming quarters.

Q2 2026 guidance was set at $680–$700 million, well ahead of the $642.9 million analyst consensus at the time of reporting. Full-year 2026 Adjusted EBITDA guidance was updated to $275–$350 million, reflecting the expectation that restructuring costs will not recur and that operating leverage will rebuild as the branded product mix stabilizes.

Market Reaction and Outlook

HIMS shares fell approximately 11%–13% in after-hours trading, reflecting investor unease with the magnitude of the earnings miss and the pace of gross margin erosion. The stock had already declined materially from its prior-year highs, compounding the sensitivity to any downside surprise.

The road ahead for Hims & Hers is framed by a high-stakes bet: that a leaner, branded GLP-1-anchored weight loss offering, combined with rapid international expansion, diagnostic infrastructure investment, and a growing multi-specialty subscriber base, can deliver the kind of platform-level scale that justifies its long-term financial targets. With Q2 guidance comfortably ahead of consensus and 2.6 million subscribers anchoring recurring revenue, the structural underpinnings remain intact — even as the transition exacts its near-term toll.

Mentioned tickers: HIMS